An observational study in Aortic Valve Disease, Aortic Valve Stenosis and Heart Valve Diseases, sponsored by Fundación EPIC. Active, not recruiting at 13 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Fundación EPIC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Aortic Valve Stenosis with a site in Spain — 25 open to participants now, 32 under way, 1 of them phase 3. Aortic Valve Stenosis · Spain.
Among the 83 studies in Aortic Valve Stenosis with a site in Spain, this one is the 18th largest by planned enrollment of the 46 observational ones that give a count, is one of 9 that started in 2023, is one of 46 observational ones, reaches primary completion later than 16 of the 31 other live ones, and was the 61st registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →25 of the 83 studies in Aortic Valve Stenosis with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18+
Fundación EPIC · Sites in Spain
Ages 18+
Biosensors Europe SA · Sites in Spain
Ages 18+
Ceric Sàrl · Sites in Spain, Austria, Estonia and 11 more countries
Ages 65–75
Shanghai MicroPort CardioFlow Medtech Co., Ltd. · Sites in Spain, Ireland, Italy and 2 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 7
First in 2006; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 585 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 209 across the 37 interventional studies, 373 across the 46 observational. Of the 42 that completed or were terminated, 9 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 83 have an industry lead sponsor. The 10 most frequent:
Fundación EPIC is the lead sponsor of 48 studies on the registry; 19 are open to participants now.
Fundación EPIC has 4 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05758909Fundación EPICEvaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation | 2026-12-01 |
| NCT06833762Hospital Clinic of BarcelonaClinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI | 2027-06 |
| NCT05283356Fundacin Biomedica Galicia SurSingle Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation | 2027-06-30 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
| NCT06049654Fundación EPICComparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 83 studies in Aortic Valve Stenosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).
Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
This study's planned enrollment of 585 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →Fundación EPIC is the lead sponsor of 48 studies on the registry; 19 are open to participants now.
Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients undergoing scheduled transfemoral TAVI implantation, performed on an outpatient basis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet all of the following conditions will be included:
Exclusion Criteria:
Patients who do not meet any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TF TAVI
Device: TF TAVI
Follow-up Observation of patients having received a TF-TAVI
Assessment of early safety
Proportion of patients with early safety defined as: * Cardiovascular death. * Stroke. * Myocardial Infarction. * Hospitalization for any reason . * Major vascular complications. * Need for pacemakers.
Time frame: 30 days
Assessment of Cardiovascular death
Assessment of Cardiovascular death
Time frame: 30 days
Assessment of Cardiovascular death
Assessment of Cardiovascular death
Time frame: 12 months
Assessment of Stroke
Incidence of patients with stroke diagnosed by a Neurologist according to VARC 3 criteria
Time frame: 30 days
Assessment of Stroke
Incidence of patients with stroke diagnosed by a Neurologist according to VARC 3 criteria
Time frame: 12 months
Assessment of Myocardial Infarction
Incidence of patients with Myocardial Infarction diagnosed by Cardiologist according to VARC 3 criteria
Time frame: 30 days
Assessment of Myocardial Infarction
Incidence of patients with Myocardial Infarction diagnosed by Cardiologist according to VARC 3 criteria
Time frame: 12 months
Assessment of Hospitalization for any reason
Incidence of patients with Hospitalization for any reason according to VARC 3 criteria
Time frame: 30 days
Assessment of Hospitalization for any reason
Incidence of patients with Hospitalization for any reason according to VARC 3 criteria
Time frame: 12 months
Assessments of Major Vascular Complications
Incidence of patients with Major Vascular Complications according to VARC 3 criteria
Time frame: 30 days
Assessments of Major Vascular Complications
Incidence of patients with Major Vascular Complications according to VARC 3 criteria
Time frame: 12 months
Assessments of need for pacemakers
Incidence of patients with need for pacemakers according to VARC 3 criteria
Time frame: 30 days
Assessments of need for pacemakers
Incidence of patients with need for pacemakers according to VARC 3 criteria
Time frame: 12 months
Assessment of hospitalization time
Incidence of patients with hospitalization according to VARC 3 criteria
Time frame: at discharge
Assessment of hospitalization due cardiac reasons
Incidence of patients with hospitalization due cardiac reasons according to VARC 3 criteria
Time frame: 12 months
Assessment of hospitalization due cardiac reasons
Incidence of patients with hospitalization due cardiac reasons according to VARC 3 criteria
Time frame: 30 days
Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 43 months is close to that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación EPIC